Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE Trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Vitamin K Intake and Atherosclerotic Cardiovascular Disease in the Danish Diet Cancer and Health Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Risk of Physical Injury for Dispatched Citizen Responders to Out-of-Hospital Cardiac Arrest

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Time Trends in Simple Congenital Heart Disease Over 39 Years: A Danish Nationwide Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Intensive Lifestyle Intervention Increases Plasma Midregional Proatrial Natriuretic Peptide Concentrations in Overweight Children

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Effect of liraglutide on expression of inflammatory genes in type 2 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Incidence and impact of parvovirus B19 infection in seronegative solid organ transplant recipients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Background Sodium-glucose cotransporter 2 inhibitors reduce hospitalizations for heart failure and cardiovascular death, although the underlying mechanisms have not been resolved. The SIMPLE trial (The Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus) investigated the effects of empagliflozin on myocardial flow reserve (MFR) reflecting microvascular perfusion, in patients with type 2 diabetes mellitus at high cardiovascular disease risk. Methods and Results We randomized 90 patients to either empagliflozin 25 mg once daily or placebo for 13 weeks, as add-on to standard therapy. The primary outcome was change in MFR at week 13, quantified by Rubidium-82 positron emission tomography/computed tomography. The secondary key outcomes were changes in resting rate-pressure product adjusted MFR, changes to myocardial flow during rest and stress, and reversible cardiac ischemia. Mean baseline MFR was 2.21 (95% CI, 2.08-2.35). There was no change from baseline in MFR at week 13 in either the empagliflozin: 0.01 (95% CI, -0.18 to 0.21) or placebo groups: 0.06 (95% CI, -0.15 to 0.27), with no treatment effect -0.05 (95% CI, -0.33 to 0.23). No effects on the secondary outcome parameters by Rubidium-82 positron emission tomography/computed tomography was observed. Treatment with empagliflozin reduced hemoglobin A1c by 0.76% (95% CI, 1.0-0.5; P<0.001) and increased hematocrit by 1.69% (95% CI, 0.7-2.6; P<0.001). Conclusions Empagliflozin did not improve MFR among patients with type 2 diabetes mellitus and high cardiovascular disease risk. The present study does not support that short-term improvement in MFR explains the reduction in cardiovascular events observed in the outcome trials. Registration URL: https://clinicaltrialsregister.eu/; Unique identifier: 2016-003743-10.

OriginalsprogEngelsk
Artikelnummere020418
TidsskriftJournal of the American Heart Association
Vol/bind10
Udgave nummer15
Sider (fra-til)e020418
ISSN2047-9980
DOI
StatusUdgivet - 3 aug. 2021

ID: 66942749